VEGFA and renal cell carcinoma: The phase 2 single-arm ORCHID trial is examining the efficacy of single-agent olaparib in 11 patients with pretreated advanced RCC harboring select DDR alterations who progressed after ICI and/or VEGF TKI (NCT03786796).